PL3297654T3 - Leczenie pobariatrycznej hipoglikemii eksendyną (9-39) - Google Patents

Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)

Info

Publication number: PL3297654T3
Authority: PL; Poland
Prior art keywords: exendin; post; treatment; bariatric hypoglycemia; bariatric
Prior art date: 2015-05-22

Application number

PL16800621T

Other languages

English (en)

Inventor

Tracey L. MCLAUGHLIN

Colleen M. CRAIG

Original Assignee

The Board Of Trustees Of The Leland Stanford Junior University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-22

Filing date

2016-05-23

Publication date

2021-12-20

2016-05-23 Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University

2021-12-20 Publication of PL3297654T3 publication Critical patent/PL3297654T3/pl

Links

WSEVKKHALHSUMB-RYVRVIGHSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O WSEVKKHALHSUMB-RYVRVIGHSA-N 0.000 title 1
208000013016 Hypoglycemia Diseases 0.000 title 1
108010024703 exendin (9-39) Proteins 0.000 title 1
230000002218 hypoglycaemic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL16800621T 2015-05-22 2016-05-23 Leczenie pobariatrycznej hipoglikemii eksendyną (9-39) PL3297654T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562165743P	2015-05-22	2015-05-22
US201562254175P	2015-11-11	2015-11-11
US201662329850P	2016-04-29	2016-04-29
PCT/US2016/033837 WO2016191395A1 (en)	2015-05-22	2016-05-23	Treatment of post-bariatric hypoglycemia with exendin(9-39)
EP16800621.1A EP3297654B1 (en)	2015-05-22	2016-05-23	Treatment of post-bariatric hypoglycemia with exendin(9-39)

Publications (1)

Publication Number	Publication Date
PL3297654T3 true PL3297654T3 (pl)	2021-12-20

Family

ID=57393681

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL16800621T PL3297654T3 (pl)	2015-05-22	2016-05-23	Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
PL16800620T PL3297653T3 (pl)	2015-05-22	2016-05-23	Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL16800620T PL3297653T3 (pl)	2015-05-22	2016-05-23	Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1

Country Status (18)

Country	Link
US (10)	US10660937B2 (pl)
EP (4)	EP3978011B1 (pl)
AU (6)	AU2016267057B2 (pl)
BR (2)	BR112017025000A2 (pl)
CA (2)	CA3024358A1 (pl)
CL (2)	CL2017002911A1 (pl)
CY (2)	CY1124616T1 (pl)
DK (2)	DK3297654T3 (pl)
ES (2)	ES2887723T3 (pl)
HR (2)	HRP20211768T1 (pl)
HU (2)	HUE057301T2 (pl)
LT (2)	LT3297653T (pl)
PL (2)	PL3297654T3 (pl)
PT (2)	PT3297653T (pl)
RS (2)	RS62368B1 (pl)
SI (2)	SI3297654T1 (pl)
SM (2)	SMT202100488T1 (pl)
WO (2)	WO2016191394A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3456340T1 (sl)	2007-01-08	2022-08-31	The Trustees Of The University Of Pennsylvania	Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
LT3297653T (lt)	2015-05-22	2022-01-10	The Board Of Trustees Of The Leland Stanford Junior University	Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
LT3541366T (lt) *	2016-11-21	2025-03-10	Amylyx Pharmaceuticals, Inc.	Eksendino (9-39) buferiniai preparatai
US20210030847A1 (en) *	2018-01-23	2021-02-04	Xeris Pharmaceuticals, Inc.	Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
GB201816639D0 (en) *	2018-10-12	2018-11-28	Heptares Therapeutics Ltd	GLP-1 Receptor Antagonist
CN112867730A (zh) *	2018-10-15	2021-05-28	艾格尔峰生物制药有限公司	用于治疗高胰岛素低血糖症的阿维西特
EP3908274A1 (en) *	2019-01-11	2021-11-17	Universitätsspital Basel	Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) *	2022-08-21	2024-02-29	M. Arkin (1999) Ltd	Glp-1 receptor antagonist and methods of use thereof
CN121219002A (zh) *	2023-04-21	2025-12-26	小利兰斯坦福大学董事会	Glp-1r拮抗作用改善胃肠外科手术后的营养
WO2025235995A1 (en) *	2024-05-10	2025-11-13	The Board Of Trustees Of The Leland Stanford Junior University	Use of glp-1 receptor agonists alone or in combination with other gastrointestinal hormones that delay gastric emptying for treatment of postbariatric hypoglycemia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0969016A2 (en)	1992-06-15	2000-01-05	Scios Inc.	Glucagon-like peptide and insulinotropin derivates
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en)	1996-08-06	2004-05-13	Yeda Research And Development Co., Ltd	Long-acting exendins and exendin agonists
ATE493998T1 (de)	1996-08-08	2011-01-15	Amylin Pharmaceuticals Inc	Pharmazeutische zusammensetzung mit einem exendin-4-peptid
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
DE122007000044I2 (de)	1997-01-07	2011-05-05	Amylin Pharmaceuticals Inc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
ATE197408T1 (de)	1998-01-30	2000-11-11	Novo Nordisk As	Eine injektionsspritze
ATE288268T1 (de)	1998-12-10	2005-02-15	Agouron Pharma	Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
US6902744B1 (en)	1999-01-14	2005-06-07	Amylin Pharmaceuticals, Inc.	Exendin agonist formulations and methods of administration thereof
ES2278589T3 (es)	1999-01-14	2007-08-16	Amylin Pharmaceuticals, Inc.	Excendinas destinadas a la inhibicion de glucagon.
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6903074B1 (en)	1999-06-04	2005-06-07	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	Neuromedin b and somatostatin receptor agonists
US6495164B1 (en)	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
US6479065B2 (en)	2000-08-10	2002-11-12	Alkermes Controlled Therapeutics, Inc.	Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en)	2001-08-31	2004-11-30	Alkermes Controlled Therapeutics Inc. Ii	Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv)	2000-12-04	2000-12-04	Pharmacia Ab	Novel method and use
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity
WO2002081649A2 (en)	2001-04-06	2002-10-17	The Trustees Of The University Of Pennsylvania	ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
CN1162446C (zh)	2001-05-10	2004-08-18	上海华谊生物技术有限公司	促胰岛素分泌肽衍生物
GB0113179D0 (en)	2001-05-31	2001-07-25	Novartis Ag	Organic compounds
EP1432430A4 (en)	2001-08-28	2006-05-10	Lilly Co Eli	PREMIXTURES OF GLP-1 AND BASALINSULIN
US7378385B2 (en)	2002-08-08	2008-05-27	University Of Cincinnati	Role for GLP-1 to mediate responses to disparate stressors
WO2004080486A1 (ja)	2003-03-13	2004-09-23	Mitsubishi Pharma Corporation	腫瘍形成抑制剤
DK3300721T4 (da)	2003-11-20	2025-03-03	Novo Nordisk As	Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
US8617613B2 (en)	2004-04-15	2013-12-31	Alkermes Pharma Ireland Limited	Polymer-based sustained release device
US7456254B2 (en)	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
DE102004043153B4 (de)	2004-09-03	2013-11-21	Philipps-Universität Marburg	Erfindung betreffend GLP-1 und Exendin
EP1888031B1 (en)	2005-06-06	2013-01-23	Camurus Ab	Glp-1 analogue formulations
PL1971362T3 (pl)	2005-08-19	2015-05-29	Amylin Pharmaceuticals Llc	Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
AR060487A1 (es)	2006-04-21	2008-06-18	Xoma Technology Ltd	Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
WO2007139941A2 (en)	2006-05-26	2007-12-06	Amylin Pharmaceuticals, Inc.	Composition and methods for treatment of congestive heart failure
SI3456340T1 (sl)	2007-01-08	2022-08-31	The Trustees Of The University Of Pennsylvania	Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma
EP2144649B1 (de)	2007-04-05	2011-07-20	Tecpharma Licensing AG	Verabreichungsvorrichtung mit funktionalem antriebsglied
DE102007016811A1 (de)	2007-04-05	2008-10-09	Tecpharma Licensing Ag	Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
WO2008133908A2 (en)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
US20110046053A1 (en)	2008-05-05	2011-02-24	Oramed Ltd.	Methods and compositions for oral administration of exenatide
WO2009143285A2 (en)	2008-05-21	2009-11-26	Amylin Pharmaceuticals, Inc.	Exendins to lower cholestrol and triglycerides
EP2303226B1 (en)	2008-06-25	2016-03-23	Endo Pharmaceuticals Solutions Inc.	Sustained delivery of exenatide and other polypeptides
WO2010003939A1 (en) *	2008-07-08	2010-01-14	Novartis Ag	Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
SI2341905T2 (sl)	2008-09-04	2024-02-29	Amylin Pharmaceuticals, Llc	Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
SG174355A1 (en)	2009-04-03	2011-10-28	Nestec Sa	Improvement in promotion of healthy catch-up growth
WO2010144508A1 (en)	2009-06-08	2010-12-16	Amunix Operating Inc.	Glucose-regulating polypeptides and methods of making and using same
WO2011109787A1 (en)	2010-03-05	2011-09-09	Conjuchem, Llc	Methods of administering insulinotropic peptides
WO2012012352A2 (en)	2010-07-19	2012-01-26	Amidebio, Llc	Modified peptides and proteins
US8969293B2 (en)	2010-12-23	2015-03-03	Rani Therapeutics, Llc	Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140256626A1 (en)	2011-10-18	2014-09-11	Prolynx Llc	Peg conjugates of exenatide
WO2013120022A2 (en)	2012-02-08	2013-08-15	Seneb Biosciences, Inc.	Treatment of hypoglycemia
EP4527855A3 (en)	2012-03-26	2025-06-11	Sanofi	Stable igg4 based binding agent formulations
US20160185837A1 (en)	2013-08-16	2016-06-30	Medimmune Limited	Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
LT3297653T (lt)	2015-05-22	2022-01-10	The Board Of Trustees Of The Leland Stanford Junior University	Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
LT3541366T (lt)	2016-11-21	2025-03-10	Amylyx Pharmaceuticals, Inc.	Eksendino (9-39) buferiniai preparatai
IL318291A (en)	2022-08-05	2025-03-01	Univ Indiana Res & Tech Corp	Glucagon-like peptide 1 receptor antibodies

2016
- 2016-05-23 LT LTEPPCT/US2016/033836T patent/LT3297653T/lt unknown
- 2016-05-23 HU HUE16800620A patent/HUE057301T2/hu unknown
- 2016-05-23 SM SM20210488T patent/SMT202100488T1/it unknown
- 2016-05-23 EP EP21194982.1A patent/EP3978011B1/en active Active
- 2016-05-23 PT PT16800620T patent/PT3297653T/pt unknown
- 2016-05-23 HU HUE16800621A patent/HUE055728T2/hu unknown
- 2016-05-23 US US15/576,646 patent/US10660937B2/en active Active
- 2016-05-23 BR BR112017025000-4A patent/BR112017025000A2/pt not_active Application Discontinuation
- 2016-05-23 PL PL16800621T patent/PL3297654T3/pl unknown
- 2016-05-23 WO PCT/US2016/033836 patent/WO2016191394A1/en not_active Ceased
- 2016-05-23 HR HRP20211768TT patent/HRP20211768T1/hr unknown
- 2016-05-23 SI SI201631300T patent/SI3297654T1/sl unknown
- 2016-05-23 DK DK16800621.1T patent/DK3297654T3/da active
- 2016-05-23 HR HRP20211285TT patent/HRP20211285T1/hr unknown
- 2016-05-23 US US15/576,647 patent/US10639354B2/en active Active
- 2016-05-23 WO PCT/US2016/033837 patent/WO2016191395A1/en not_active Ceased
- 2016-05-23 BR BR112017024997-9A patent/BR112017024997A2/pt not_active Application Discontinuation
- 2016-05-23 AU AU2016267057A patent/AU2016267057B2/en active Active
- 2016-05-23 CA CA3024358A patent/CA3024358A1/en active Pending
- 2016-05-23 PL PL16800620T patent/PL3297653T3/pl unknown
- 2016-05-23 SM SM20210668T patent/SMT202100668T1/it unknown
- 2016-05-23 RS RS20211073A patent/RS62368B1/sr unknown
- 2016-05-23 CA CA3024353A patent/CA3024353A1/en active Pending
- 2016-05-23 ES ES16800621T patent/ES2887723T3/es active Active
- 2016-05-23 ES ES16800620T patent/ES2897955T3/es active Active
- 2016-05-23 EP EP21176474.1A patent/EP3936143A1/en active Pending
- 2016-05-23 SI SI201631362T patent/SI3297653T1/sl unknown
- 2016-05-23 LT LTEPPCT/US2016/033837T patent/LT3297654T/lt unknown
- 2016-05-23 AU AU2016267052A patent/AU2016267052B2/en active Active
- 2016-05-23 DK DK16800620.3T patent/DK3297653T3/da active
- 2016-05-23 EP EP16800620.3A patent/EP3297653B1/en active Active
- 2016-05-23 PT PT168006211T patent/PT3297654T/pt unknown
- 2016-05-23 RS RS20211458A patent/RS62627B1/sr unknown
- 2016-05-23 EP EP16800621.1A patent/EP3297654B1/en active Active
2017
- 2017-11-16 CL CL2017002911A patent/CL2017002911A1/es unknown
- 2017-11-16 CL CL2017002913A patent/CL2017002913A1/es unknown
2020
- 2020-03-09 US US16/813,535 patent/US10993991B2/en active Active
- 2020-03-09 US US16/813,536 patent/US10993992B2/en active Active
2021
- 2021-04-09 US US17/226,161 patent/US11622995B2/en active Active
- 2021-04-09 US US17/226,164 patent/US11617782B2/en active Active
- 2021-09-01 CY CY20211100779T patent/CY1124616T1/el unknown
- 2021-11-29 CY CY20211101046T patent/CY1125147T1/el unknown
2022
- 2022-03-22 AU AU2022201973A patent/AU2022201973B2/en active Active
- 2022-04-14 AU AU2022202506A patent/AU2022202506B2/en active Active
2023
- 2023-02-22 US US18/172,543 patent/US12220444B2/en active Active
- 2023-02-22 US US18/172,546 patent/US12102663B2/en active Active
2024
- 2024-06-17 US US18/745,091 patent/US20250082730A1/en active Pending
2025
- 2025-01-02 US US19/008,248 patent/US20250255935A1/en active Pending
- 2025-08-13 AU AU2025217292A patent/AU2025217292A1/en active Pending
- 2025-08-22 AU AU2025220813A patent/AU2025220813A1/en active Pending

Also Published As

Publication number	Publication date
EP3297653A1 (en)	2018-03-28
LT3297653T (lt)	2022-01-10
HUE055728T2 (hu)	2021-12-28
US11622995B2 (en)	2023-04-11
BR112017024997A2 (pt)	2018-07-31
AU2016267057B2 (en)	2021-12-23
AU2022201973B2 (en)	2025-05-15
HRP20211768T1 (hr)	2022-02-18
US20230346890A1 (en)	2023-11-02
US10660937B2 (en)	2020-05-26
US12220444B2 (en)	2025-02-11
AU2022202506B2 (en)	2025-06-05
CL2017002913A1 (es)	2018-06-01
CY1125147T1 (el)	2023-03-24
DK3297654T3 (da)	2021-09-06
WO2016191394A1 (en)	2016-12-01
EP3297654B1 (en)	2021-07-07
EP3297653A4 (en)	2018-12-26
US20210315974A1 (en)	2021-10-14
SI3297653T1 (sl)	2022-01-31
ES2897955T3 (es)	2022-03-03
HRP20211285T1 (hr)	2022-01-07
EP3936143A1 (en)	2022-01-12
ES2887723T3 (es)	2021-12-27
US10993991B2 (en)	2021-05-04
EP3297653B1 (en)	2021-09-15
RS62627B1 (sr)	2021-12-31
US12102663B2 (en)	2024-10-01
US10639354B2 (en)	2020-05-05
US20200276271A1 (en)	2020-09-03
US20240000894A1 (en)	2024-01-04
US10993992B2 (en)	2021-05-04
US20210290731A1 (en)	2021-09-23
BR112017025000A2 (pt)	2018-08-07
AU2025220813A1 (en)	2025-09-11
CL2017002911A1 (es)	2018-05-25
SMT202100668T1 (it)	2022-01-10
AU2022201973A1 (en)	2022-04-14
US20180147261A1 (en)	2018-05-31
EP3297654A4 (en)	2018-04-11
US20200276272A1 (en)	2020-09-03
AU2016267052A1 (en)	2017-12-14
AU2016267052B2 (en)	2022-01-20
US20250255935A1 (en)	2025-08-14
SMT202100488T1 (it)	2021-11-12
PT3297654T (pt)	2021-09-06
AU2025217292A1 (en)	2025-09-04
LT3297654T (lt)	2021-10-25
SI3297654T1 (sl)	2021-11-30
EP3978011B1 (en)	2026-05-06
HUE057301T2 (hu)	2022-05-28
AU2022202506A1 (en)	2022-05-12
PT3297653T (pt)	2021-10-25
CA3024353A1 (en)	2016-12-01
RS62368B1 (sr)	2021-10-29
CY1124616T1 (el)	2022-07-22
DK3297653T3 (da)	2021-10-18
EP3297654A1 (en)	2018-03-28
CA3024358A1 (en)	2016-12-01
EP3978011A1 (en)	2022-04-06
US11617782B2 (en)	2023-04-04
WO2016191395A1 (en)	2016-12-01
AU2016267057A1 (en)	2017-12-14
PL3297653T3 (pl)	2022-01-31
US20250082730A1 (en)	2025-03-13
US20180117122A1 (en)	2018-05-03

Publication	Publication Date	Title
PL3297654T3 (pl)	2021-12-20	Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
SG10202100803WA (en)	2021-03-30	Endoscope with pannable camera and related method
ZA201706059B (en)	2023-08-30	Method of treatment with tradipitant
GB201502137D0 (en)	2015-03-25	Treatment
IL252803A0 (en)	2017-08-31	Formulation with a constant ratio of insulin glargine/licisanitide
GB201522243D0 (en)	2016-01-27	Treatment
GB201519450D0 (en)	2015-12-16	Novel treatment
IL254500A0 (en)	2017-11-30	Treatment of patients with type 2 diabetes
GB201508841D0 (en)	2015-07-01	Treatment
PL3139948T3 (pl)	2020-08-10	Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
IL247218A0 (en)	2016-09-29	Treatment of infections caused by h. pylori using mtan inhibitors
GB201513543D0 (en)	2015-09-16	Compositions for use in the treatment of diabetes
GB201503008D0 (en)	2015-04-08	Treatment
GB201414366D0 (en)	2014-09-24	Blood defence
AU2015904246A0 (en)	2015-11-05	Treatment of diabetes
HUE048860T2 (hu)	2020-09-28	1-es típusú cukorbetegség kezelése GLP-1 és anti-IL-21 alkalmazásával
AU2016901862A0 (en)	2016-06-02	Treatment of diabetes
GB201513922D0 (en)	2015-09-23	Treatment of hyperpigmentation
GB201518349D0 (en)	2015-12-02	Treatment
GB201515739D0 (en)	2015-10-21	Treatment
GB201514008D0 (en)	2015-09-23	Treatment
GB201604099D0 (en)	2016-04-20	Insulin biosensor
AU2015902668A0 (en)	2015-07-16	Fast acting hypoglycaemic treatment ( Hypo-fast)
EP3093013A4 (en)	2017-09-13	Agent for treating diabetes
GB201407396D0 (en)	2014-06-11	Confectionary treatment